127 related articles for article (PubMed ID: 25043210)
1. Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement.
Slavik T; Asselah F; Fakhruddin N; El Khodary A; Torjman F; Anis E; Quinn M; Khankan A; Kerr KM
Clin Lung Cancer; 2014 Nov; 15(6):398-404. PubMed ID: 25043210
[TBL] [Abstract][Full Text] [Related]
2. Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine.
Murgu S; Colt H
Clin Lung Cancer; 2013 Nov; 14(6):609-26. PubMed ID: 24188629
[TBL] [Abstract][Full Text] [Related]
3. Strategies for improving outcomes in NSCLC: a look to the future.
Stahel R; Peters S; Baas P; Brambilla E; Cappuzzo F; De Ruysscher D; Eberhardt WE; Felip E; Fennell D; Marchetti A; Paz-Ares L; Adjei AA
Lung Cancer; 2013 Dec; 82(3):375-82. PubMed ID: 24094287
[TBL] [Abstract][Full Text] [Related]
4. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
Rossi G; Graziano P; Leone A; Migaldi M; Califano R
Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment.
Sudhindra A; Ochoa R; Santos ES
Clin Lung Cancer; 2011 Nov; 12(6):360-8. PubMed ID: 21729648
[TBL] [Abstract][Full Text] [Related]
8. Molecular predictive and prognostic markers in non-small-cell lung cancer.
Coate LE; John T; Tsao MS; Shepherd FA
Lancet Oncol; 2009 Oct; 10(10):1001-10. PubMed ID: 19796752
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer biomarkers: present status and future developments.
Cagle PT; Allen TC; Olsen RJ
Arch Pathol Lab Med; 2013 Sep; 137(9):1191-8. PubMed ID: 23991729
[TBL] [Abstract][Full Text] [Related]
10. Tissue sampling in lung cancer: a review in light of the MERIT experience.
Reck M; Hermes A; Tan EH; Felip E; Klughammer B; Baselga J
Lung Cancer; 2011 Oct; 74(1):1-6. PubMed ID: 21658788
[TBL] [Abstract][Full Text] [Related]
11. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group.
Thunnissen E; Kerr KM; Herth FJ; Lantuejoul S; Papotti M; Rintoul RC; Rossi G; Skov BG; Weynand B; Bubendorf L; Katrien G; Johansson L; López-Ríos F; Ninane V; Olszewski W; Popper H; Jaume S; Schnabel P; Thiberville L; Laenger F
Lung Cancer; 2012 Apr; 76(1):1-18. PubMed ID: 22138001
[TBL] [Abstract][Full Text] [Related]
12. miRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer.
Gao W; Xu J; Shu YQ
Expert Rev Respir Med; 2011 Oct; 5(5):699-709. PubMed ID: 21955239
[TBL] [Abstract][Full Text] [Related]
13. Personalized therapy of lung cancer.
Thomas R; Wolf J
Onkologie; 2012; 35 Suppl 1():14-9. PubMed ID: 22286583
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic and predictive analyses of cytological specimens of non-small cell lung cancer: strategies and challenges].
Herth FJ; Bubendorf L; Gütz S; Morresi-Hauf A; Hummel M; Junker K; Lehmann U; Petersen I; Schnabel PA; Warth A
Pneumologie; 2013 Apr; 67(4):198-204. PubMed ID: 23576199
[TBL] [Abstract][Full Text] [Related]
15. Genomic medicine in non-small cell lung cancer: paving the path to personalized care.
Sriram KB; Larsen JE; Yang IA; Bowman RV; Fong KM
Respirology; 2011 Feb; 16(2):257-63. PubMed ID: 21044232
[TBL] [Abstract][Full Text] [Related]
16. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
17. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
18. Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancer.
Hsiao SH; Chung CL; Lee CM; Chen WY; Chou YT; Wu ZH; Chen YC; Lin SE
Clin Lung Cancer; 2013 Nov; 14(6):719-25. PubMed ID: 23891241
[TBL] [Abstract][Full Text] [Related]
19. Application of proteomics in non-small-cell lung cancer.
Cho WC
Expert Rev Proteomics; 2016; 13(1):1-4. PubMed ID: 26577456
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathology of non-small cell lung cancer: a practical guide.
Aisner DL; Marshall CB
Am J Clin Pathol; 2012 Sep; 138(3):332-46. PubMed ID: 22912349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
